transthyretin amyloidosis

Showing 1 posts of 1 posts found.


Europe approves first treatment for transthyretin amyloidosis in cardiomyopathy patients: Pfizer’s Vyndaqel

February 19, 2020
Research and Development, Sales and Marketing Europe, Pfizer, Vyndaqel, pharma, transthyretin amyloidosis

The European Commission (EC) has awarded marketing approval to Pfizer’s Vyndaqel (tafamidis), it has emerged, for the treatment of wild-type …

Latest content